Advertisement

Digestive Diseases and Sciences

, Volume 50, Issue 10, pp 1951–1958 | Cite as

An Elemental Diet Controls Inflammation in Indomethacin-Induced Small Bowel Disease in Rats: The Role of Low Dietary Fat and the Elimination of Dietary Proteins

  • Hideki Suzuki
  • Nozomi Hanyou
  • Ichiro Sonaka
  • Hisanori Minami
Article

Abstract

Elemental diets (EDs) are effective in treating Crohn's disease. We hypothesize that low dietary fat and amino acids used as the sole nitrogen source are the major contributors for the success of EDs. We examined the influences of the addition of dietary fat and protein to an ED using an indomethacin-induced inflammation model in rat small intestine. In the ED-fed rats, the intestinal damage score was decreased compared with that in the standard chow group with decreasing intestinal permeability. By supplementing an ED with soybean oil (SO), intestinal permeability was increased to a level similar to that of the standard chow group. For this group, the intestinal damage score also increased compared with that of the ED group but did not reach the levels observed in the standard chow group.The addition of dietary proteins (using heat-denatured pancreatin) resulted in intestinal damage scores that were significantly higher than those of the ED+SO-fed group. The dietary protein increased the intestinal damage score.These results suggest that EDs control inflammation by decreasing intestinal permeability and the elimination of dietary proteins.

Key Words

Crohn' disease dietary proteins elemental diet indomethacin inflammation soybean oil 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shoda R, Matsueda K, Yamato S, Umeda N: Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 63:741–745, 1996PubMedGoogle Scholar
  2. 2.
    O'Morain C, Segal AW, Levi AJ: Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J (Clin Res Ed) 288:1859–1862, 1984Google Scholar
  3. 3.
    Saverymuttu S, Hodgson HJ, Chadwick VS: Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut 26:994–998, 1985PubMedGoogle Scholar
  4. 4.
    Okada M, Yao T, Yamamoto T, Takenaka K, Imamura K, Maeda K, Fujita K: Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease. Hepatogastroenterology 37:72–80, 1990PubMedGoogle Scholar
  5. 5.
    Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, Farthing MJ, Misiewicz JJ, Silk DB: Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 34:1198–1202, 1993PubMedGoogle Scholar
  6. 6.
    Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J: Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119:23–31, 2000PubMedGoogle Scholar
  7. 7.
    Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123:689–699, 2002CrossRefPubMedGoogle Scholar
  8. 8.
    Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR: Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126:414–424, 2004CrossRefPubMedGoogle Scholar
  9. 9.
    Forcione DG, Rosen MJ, Kisiel JB, Sands BE: Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53:1117–1122, 2004CrossRefPubMedGoogle Scholar
  10. 10.
    Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, Jantschek G, Scriba PC: Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 22 (Suppl 139):41–52, 1987Google Scholar
  11. 11.
    Seibold F, Weber P, Jenss H, Wiedmann KH: Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 32:1192–1197, 1991PubMedGoogle Scholar
  12. 12.
    Tozawa T: Antibodies to porcine pancreatic amylase in inflammatory bowel disease: Characterization and prevalence. Jpn J Electroph 43:139–145, 1999Google Scholar
  13. 13.
    Haverback BJ, Dyce BJ, Gutenberg PJ, Montgomery DW: Measurement of trypsin and chymotrypsin in stool. A diagnostic test for pancreatic exocrine insufficiency. Gastroenterology 44:588–597, 1963Google Scholar
  14. 14.
    Girella E, Faggionato P, Benetazzo D, Mastella G: The assay of chymotrypsin in stool as a simple and effective test of exocrine pancreatic activity in cystic fibrosis. Pancreas 3:254–262, 1988PubMedGoogle Scholar
  15. 15.
    Moriyoshi Y, Takeuchi T, Shiratori K, Watanabe S: Fecal isoamylase activity in patients with pancreatic diseases. Pancreas 6:70–76, 1991PubMedGoogle Scholar
  16. 16.
    Muench R, Ammann R: Fecal immunoreactive lipase: a new tubeless pancreatic function test. Scand J Gastroenterol 27:289–294, 1992PubMedGoogle Scholar
  17. 17.
    Takada T, Yasuda H, Uchiyama K, Hasegawa H, Misu Y, Iwagaki T: Pancreatic enzyme activity after a pylorus-preserving pancreaticoduodenectomy reconstructed with pancreaticogastrostomy. Pancreas 11:276–282, 1995PubMedGoogle Scholar
  18. 18.
    Puspok A, Oberhuber G, Wyatt J, Maier-Dobersberger T, Hammer J, Pfeffel F, Wrba F, Potzi R, Vogelsang H: Gastroduodenal permeability in Crohn's disease. Eur J Clin Invest 28:67–71, 1998CrossRefPubMedGoogle Scholar
  19. 19.
    Soderholm JD, Peterson KH, Olaison G, Franzen LE, Westrom B, Magnusson KE, Sjodahl R: Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 117:65–72, 1999PubMedGoogle Scholar
  20. 20.
    D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC: Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 94:2956–2960, 1999CrossRefPubMedGoogle Scholar
  21. 21.
    Hilsden RJ, Meddings JB, Hardin J, Gall DG, Sutherland LR: Intestinal permeability and postheparin plasma diamine oxidase activity in the prediction of Crohn's disease relapse. Inflamm Bowel Dis 5:85–91, 1999PubMedGoogle Scholar
  22. 22.
    Arnott ID, Kingstone K, Ghosh S: Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 35:1163–1169, 2000CrossRefPubMedGoogle Scholar
  23. 23.
    Soderholm JD, Olaison G, Peterson KH, Franzen LE, Lindmark T, Wiren M, Tagesson C, Sjodahl R: Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 50:307–313, 2002CrossRefPubMedGoogle Scholar
  24. 24.
    Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB: Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17:641–662, 1993CrossRefPubMedGoogle Scholar
  25. 25.
    Anthony A, Pounder RE, Dhillon AP, Wakefield AJ: Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment Pharmacol Ther 14:241–245, 2000CrossRefPubMedGoogle Scholar
  26. 26.
    Colpaert S, Liu Z, De Greef B, Rutgeerts P, Ceuppens JL, Geboes K: Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. Aliment Pharmacol Ther 15:1827–1836, 2001CrossRefPubMedGoogle Scholar
  27. 27.
    Nakamura J, Takada S, Ohtsuka N, Heya T, Yamamoto A, Kimura T, Sezaki H: An assessment of indomethacin-induced gastrointestinal mucosal damage in-vivo: enhancement of urinary recovery after oral administration of phenolsulfonphthalein in rats. J Pharm Pharmacol 35:369–372, 1983PubMedGoogle Scholar
  28. 28.
    Chen K, Nezu R, Inoue M, Wasa M, Iiboshi Y, Fukuzawa M, Kamata S, Takagi Y, Okada A: Beneficial effects of growth hormone combined with parenteral nutrition in the management of inflammatory bowel disease: an experimental study. Surgery 121:212–218, 1997CrossRefPubMedGoogle Scholar
  29. 29.
    Giaffer MH, North G, Holdsworth CD: Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 335:816–819, 1990CrossRefPubMedGoogle Scholar
  30. 30.
    Raouf AH, Hildrey V, Daniel J, Walker RJ, Krasner N, Elias E, Rhodes JM: Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge. Gut 32:702–707, 1991PubMedGoogle Scholar
  31. 31.
    Rigaud D, Cosnes J, Le Quintrec Y, Rene E, Gendre JP, Mignon M: Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 32:1492–1497, 1991PubMedGoogle Scholar
  32. 32.
    Royall D, Jeejeebhoy KN, Baker JP, Allard JP, Habal FM, Cunnane SC, Greenberg GR: Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome. Gut 35:783–787, 1994PubMedGoogle Scholar
  33. 33.
    Verma S, Brown S, Kirkwood B, Giaffer MH: Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 95:735–739, 2000CrossRefPubMedGoogle Scholar
  34. 34.
    Leiper K, Woolner J, Mullan MM, Parker T, van der Vliet M, Fear S, Rhodes JM, Hunter JO: A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut 49:790–794, 2001CrossRefPubMedGoogle Scholar
  35. 35.
    Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, Hibi T, Iwao Y, Munakata A, Fukuda S, Matsumoto T, Oshitani N, Hiwatashi N, Oriuchi T, Kitahora T, Utsunomiya T, Saitoh Y, Suzuki Y, Nakajima M: Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol 15:151–157, 2003CrossRefPubMedGoogle Scholar
  36. 36.
    Middleton SJ, Rucker JT, Kirby GA, Riordan AM, Hunter JO: Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 14: 229–236, 1995CrossRefGoogle Scholar
  37. 37.
    Tanaka S, Miura S, Kimura H, Ohkubo N, Tsuzuki Y, Fukumura D, Serizawa H, Kurose I, Mori M, Ishii H: Amelioration of chronic inflammation by ingestion of elemental diet in a rat model of granulomatous enteritis. Dig Dis Sci 42:408–419, 1997CrossRefPubMedGoogle Scholar
  38. 38.
    Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, Nezu R, Ito T, Matsuda H, Kiyono H: Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol 165:5891–5899, 2000PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Hideki Suzuki
    • 1
    • 3
  • Nozomi Hanyou
    • 1
  • Ichiro Sonaka
    • 1
  • Hisanori Minami
    • 2
  1. 1.Pharmaceutical Research LaboratoriesAjinomoto Co., Inc.KawasakiJapan
  2. 2.Faculty of Environmental and Symbiotic SciencesPrefectural University of KumamotoKumamotoJapan
  3. 3.Pharmaceutical Research LaboratoriesAjinomoto Co., Inc.KawasakiJapan

Personalised recommendations